TET2 Expression in Bone Marrow Mononuclear Cells of Patients with Myelodysplastic Syndromes and Its Clinical Significance

Wei Zhang, Zong-hong Shao, Rong Fu, Hua-quan Wang, Li-juan Li, Jun Wang, Wen Qu, Yong Liang, Guo-jin Wang, Xiao-ming Wang, Yu-hong Wu, Hong Liu, Jia Song, Jing Guan, Li-min Xing

Abstract


Objective    To investigate the expression of TET2 mRNA and protein in the bone marrow mononuclear cells (BMMNC) of patients with myelodysplastic syndrome (MDS) and its clinical significance.
Methods    The expression of TET2 mRNA and protein in bone marrow mononuclear cells (BMMNC) of 32 patients with MDS and 20 healthy donors was examined by qPCR and Western blot.
Results    The expression of TET2 mRNA in BMMNC was down- regulated in MDS patients compared with the donor group [(0.41±0.28)% vs. (1.07±0.56)%] (P<0.001). Compared with lower expression group (TET2<0.4) [(6.53±6.17)%], patients with higher expression of TET2 (≥0.4) presented signifi  cantly lower proportion of bone marrow blasts [(1.21±1.56)%] (P<0.05). The expression of TET2 mRNA in BMMNC of MDS patients was inversely correlated with malignant clone burden (r=-0.398, P<0.05) and IPSS (r=-0.412, P<0.05). The expression of TET2 protein was down-regulated in MDS patients compared with that in the donor group.
Conclusions    The mRNA and protein expression of TET2 in BMMNC of MDS patients is decreased, which might be useful as an important parameter for the evaluation of MDS clone burden.

 


Keywords


myelodysplastic syndrome, TET2 gene, clinical features

Full Text: PDF HTML

Refbacks

  • There are currently no refbacks.



OUR FRIENDS